Please sign in with your existing account details.
Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.
Privacy statement - Terms and conditions
Forgotten your password?
You have exceeded the maximum number of login attempts for this email address and your account has been locked. An email has been sent to member of Browne Jacobson's web team and some one will be contacting you over the next two working days with details of how to change your password.
Are you sure you want to remove this item from you pinned content?
A piece in the Guardian today questions recent press coverage around primary league tables and the vulnerability of those falling below floor targets. The article states that only 1 in 5 primaries which underperformed last year have now become a sponsored academy.
The DfE’s clear policy expectation is that where schools have a history of falling below floor targets, conversion with a strong sponsor is the “normal route” to improvement. Primaries, particularly in target geographical areas, are being put under pressure to become academies. Legally however, purely being below floor targets does not mean a school can directly be forced to become an academy. A school’s Ofsted grade and the local authority’s position in terms of securing improvement as a maintained school will be important factors too.
The Guardian’s piece also mentions primaries who “narrowly avoided forced academisation”. Certainly those governing bodies concerned about results may have more choices than they think.
With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.
View blog
The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.
Our top tips for supporting transgender and non-binary pupils.
On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.
Senior Associate
Select which mailings you would like to receive from us.
Sign up